NIH Launches $2 Million Prize Competition for Fetal Diagnostic Technologies
Desired fetal diagnostic tech from the NIH includes wearable devices, in vitro diagnostic tests, imaging devices, and sensor technologies.
Desired fetal diagnostic tech from the NIH includes wearable devices, in vitro diagnostic tests, imaging devices, and sensor technologies.
The enhancement of women’s health is a focal point for many companies, and is projected to reach $75.1 billion by 2025.
Devyser Compact is a rapid genetic test for prenatal chromosome testing and is approved under the new more comprehensive regulation.
Juno Diagnostics has announced the launch of Juno Hazel, a non-invasive prenatal screening (NIPS) solution.
Read MoreThe FDA approved Roche’s companion diagnostic test to aid in identifying epithelial ovarian cancer patients eligible for targeted treatment.
Read MoreSera Prognostics’ blood-based test offers individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.
Read MoreCedars-Sinai investigators have found that a specific imbalance of two placental proteins could predict preeclampsia risk.
Read MoreDiagnostic screening for Down’s Syndrome during pregnancy was difficult until the development of an NIPT fetal fraction test.
Read MoreNew tech can capture stray ovarian cancer cells from a blood test and predict cancer in those who have a lesion or cyst in the pelvic region.
Read MoreDeclines in cardiovascular disease death rates stalled for mid-life women compared to men, suggesting sex-specific approaches may be needed.
Read MoreAACC has issued a new guidance document with expert recommendations for performing point-of-care tests for fertility and reproductive health.
Read MoreIn many parts of the U.S., broad genetic testing is offered to prospective parents and is usually also recommended in early pregnancy.
Read MoreThe MedStar Heart & Vascular Institute’s program uses the Coroventis CoroFlow Cardiovascular System for CMD diagnosis.
Read MoreHera Biotech closed a $1.9 million seed financing round to support the commercialization of its non-surgical endometriosis diagnostic test.
Read MoreDotLab announced that the U.S. Patent and Trademark Office has granted three key patents for the company’s endometriosis tests.
Read MoreNanopath will develop & commercialize a biosensing platform that aims to transform how women’s pelvic & gynecologic infections are diagnosed.
Read MoreThe Oklahoma State Public Health Laboratory transferred to a new facility in the midst of the COVID-19 crisis.
Read MoreResearchers found that women with a history of severe preeclampsia have more markers linked to brain cell damage and inflammation.
Read More